Teijin Pharma Ltd

Tokyo, Japan

Teijin Pharma Ltd

Tokyo, Japan
SEARCH FILTERS
Time filter
Source Type

Patent
Teijin Pharma Ltd | Date: 2017-05-31

Provided are a means to detect a plurality of dynamics, a processing unit that calculates a temporal change in the detected dynamics, and an evaluation device that determines exacerbation of clinical conditions in heart failure of a patient based on the calculated change in the patients dynamics over time. The present invention makes it possible to detect, early and with high accuracy, that the onset of acute heart failure is imminent.


Disclosed are crystals of 2-(5-chloropyridin-3-yl)-1-(2,5-dichlorobenzyl)-4-methyl-1H-imidazole-5-carboxylic acid useful as therapeutic or prophylactic agents for gout, hyperuricemia, and the like, and a method for producing the crystals.


Patent
Teijin Pharma Ltd | Date: 2017-03-22

Provided is a novel pyrazine derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is useful for treating or preventing diseases in which URAT1 is involved, including gout, hyperuricemia, hypertension, renal diseases such as interstitial nephritis and the like, diabetes, arteriosclerosis, Lesch-Nyhan syndrome, and the like.


Patent
Teijin Pharma Ltd | Date: 2017-08-02

Provided is an oxygen concentration device which, as an oxygen concentration device having a reduced difference in flow rates of gas which flows through a pressure equalization valve of a pressure equalization path during a purge step and a pressure equalization step, is provided at at least one end side of the pressure equalization valve with a pressure control member having a difference in pressure loss due to the direction of gas flow so that pressure loss of the gas which flows through the pressure equalization path in one direction becomes nearly equal to that of the gas which flows therethrough in the opposite direction.


Patent
Teijin Pharma Ltd | Date: 2017-08-16

The present invention provides a tablet comprising a plurality of drug-containing parts and at least one connecting part adhered to the drug-containing parts, and having a scored line capable of dividing the whole tablet on the connecting part; particularly, a coated tablet in which a connecting part and a coating layer have the same or different drug release controlling functions; a tablet having an insoluble coating on a drug-containing part having a scored line, wherein the drug-containing part has a structure or composition such that the drug is substantially released after the tablet is divided along the scored line and then ingested; and a tablet comprising a plurality of drug-containing parts and at least one connecting part adhered to the drug-containing parts, wherein at least two drug-containing parts have different compositions. In addition, the present invention provides a method of manufacturing a tablet, wherein a column comprising a plurality of columnar pharmaceutical composition layers having the same cross-section and laminated in the axial direction of the column is compression molded and then compression molded in a direction different from the axial direction of the column.


Patent
Teijin Pharma Ltd | Date: 2017-06-07

There are provided crystals of 2-[4-(2,2-dimethylpropoxy)-3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid which is useful as a therapeutic agent or prophylactic agent for gout, hyperuricemia and the like.


Patent
Teijin Pharma Ltd | Date: 2017-06-07

There are provided: 4-methyl-2-[4-(2-methylpropoxy)-3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]-1,3-thiazole-5-carboxylic acid, a sodium salt thereof and crystals of these, useful as a therapeutic agent and a prophylactic agent for gout, hyperuricemia and the like, and a method for producing the same.


Patent
Teijin Pharma Ltd | Date: 2017-08-16

The purpose of the invention is to provide a transcranial magnetic stimulation system capable of guiding a patient into an optimum posture for treatment. The system 1 of the invention includes an optical device 502 for projecting a light spot 805 to a head of a patient and detecting a reflection light of the light spot; a memory means 71 for memorizing information included in the reflection light detected by the optical device as a reference information when the projected light spot on the patient overlaps a marking (800) provided on the patient; a calculation means 72 for using the reference information memorized in the memory means and a comparison information included in the reflection light of the light spot to calculate an overlap ratio between the marking and the light spot corresponding to the comparison information; and a display means 504 for displaying the overlap ratio.


A rehabilitation assistance device (1), provided with: an arm part (30) having a holding part (20) for holding a part of the upper limb or the lower limb of a user, the arm part (30) movably supporting the holding part (20); a memory unit (80) for storing training information, the memory unit (80) storing first training information defined in advance; a motion information acquisition unit (61) for acquiring motion information associated with the movement of the holding part (20), the motion information acquisition unit (61) acquiring first motion information for the holding part (20) moved on the basis of the first training information; a motion evaluation unit (72) for generating evaluation information in which the motion information is evaluated, the motion evaluation unit (72) evaluating the first motion information and generating first evaluation information; and a display (40) for displaying at least one of the training information, the motion information, and the evaluation information.


Patent
Teijin Pharma Ltd and Amgen Inc. | Date: 2017-01-04

The present invention relates to a novel compound having a function of inhibiting ROR activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.

Loading Teijin Pharma Ltd collaborators
Loading Teijin Pharma Ltd collaborators